# US 2008/0269503 A1 · Processes for preparing darifenacin hydrobromide

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0269503 A1
- Document ID: US20080269503A1
- Status: Published application
- Kind: A1
- Application number: 12/217,204
- Filed: 2008-07-01
- Published: 2008-10-30
- Earliest claimed: 2005-12-27
- Assignees: Teva Pharmaceuticals USA, Inc. for Barbados; Teva Pharmaceutical Industries Ltd.
- Inventors: Valeriano Merli; Augusto Canavesi; Paola Daverio
- Web page: https://patentgrep.com/patent/US20080269503A1

## CPC

- C07D 405/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61P 13/00: Drugs for disorders of the urinary system
- C07D 207/09: Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D 207/48: Sulfur atoms
- C07D 307/79: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention encompasses processes for the preparation of darifenacin hydrobromide.

## Claims

### Claim 1

A process for preparing darifenacin hydrobromide comprising:
a) combining 3-(S)-(+)-hydroxypyrrolidine, a solvent selected from the group consisting of a C6-9 aromatic hydrocarbon, a polar aprotic organic solvent, and mixtures thereof, a sulfonyl halide, and a base to obtain 1-X-sulfonyl-3-(S)-(−)-X-sulfonyloxypyrrolidine of formula I,
b) reacting the 1-X-sulfonyl-3-(S)-(−)-X-sulfonyloxypyrrolidine of formula I, diphenylacetonitrile, and an inorganic base, in an organic solvent selected from the group consisting of a C6-9 aromatic hydrocarbon, a polar aprotic organic solvent, and mixtures thereof, to obtain (S)-2,2-diphenyl-2-(1-X-sulfonyl-3-pyrrolidinil)acetonitrile of formula II;
c) reacting the (S)-2,2-diphenyl-2-(1-X-sulfonyl-3-pyrrolidinil)acetonitrile intermediate of formula II, a bromine acceptor selected from the group consisting of phenol and naphthol, and an acid to obtain (S)-2,2-diphenyl-2-(3-pyrrolidinil) acetonitrile salt of formula III,
wherein the bromine acceptor is phenol only when the acid is HBr;
d) combining the (S)-2,2-diphenyl-2-(3-pyrrolidinil)acetonitrile salt of formula III, a compound of the formula V,
a solvent selected from the group consisting of a C6-9 aromatic hydrocarbon, a polar organic solvent, water, and mixtures thereof, and a base to obtain a mixture;
e) heating the mixture of step d;
f) admixing the mixture of step d with an acid to obtain a (S)-2-{1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]-3-pyrrolidinyl}-2,2-acetonitrile salt of formula IV; and
g) admixing the (S)-2-{1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]-3-pyrrolidinyl}-2,2-acetonitrile salt of formula IV, an inorganic base and a protic solvent; and
h) reacting with hydrobromic acid to obtain darifenacin hydrobromide, wherein X is either C1-10 alkyl or C6-9 aryl, wherein Y is a leaving group selected from the group consisting of I, Cl, Br, mesyl, tosyl, brosyl, trifluoroacetyl, and trifluoromethansulfonyl, wherein Z1 and Z2 are independently an acid.

### Claim 2 (depends on 1)

The process of claim 1, wherein X is C6-9 aryl.

### Claim 3 (depends on 1)

The process of claim 1, wherein X is tolyl.

### Claim 4 (depends on 1)

The process of claim 1, wherein Y is Cl.

### Claim 5 (depends on 1)

The process of claim 1, wherein Z1 and Z2 are independently HBr or HCl.

### Claim 6 (depends on 1)

The process of claim 1, further comprising recovering the darifenacin hydrobromide.
